Bibliography
- Budnitz DS , PollockDA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL: National surveillance of emergency department visits for outpatient adverse drug events. JAMA296 , 1858–1866 (2006).
- Pirmohamed M , JamesS, MeakinS et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ329 , 15–19 (2004).
- Dormann H , NeubertA, Criegee-Rieck M et al.: Readmissions and adverse drug reactions in internal medicine: the economic impact. J. Intern. Med.255 , 653–663 (2004).
- Otero Lopez MJ , Alonso Hernandez P, Maderuelo Fernandez JA, Ceruelo Bermejo J, Dominguez-Gil Hurle A, Sanchez Rodriguez A: Prevalence and factors associated with preventable adverse drug events leading to hospital admission. Farm. Hosp.30 , 161–170 (2006).
- Queneau P , BannwarthB, CarpentierF et al.; on behalf of Association Pedagogique Nationale pour l‘Enseignement de la Therapeutique (APNET): Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf.30 , 81–88 (2007).
- Schnipper JL , KirwinJL, CotugnoMC et al.: Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch. Intern. Med.166 , 565–571 (2006).
- Davidson A : Preventing adverse drug events.CMAJ176 , 67–68 (2007).
- Leonard MS , CiminoM, ShahaS, McDougal S, Pilliod J, Brodsky L: Risk reduction for adverse drug events through sequential implementation of patient safety initiatives in a children‘s hospital. Pediatrics118 , E1124–E1129 (2006).
- Young D : Electronic system alerts pharmacists to potential adverse drug events.Am. J. Health Syst. Pharm.58 , 2362–2365 (2001).
- Hurdle JF , WeirCR, RothB, HoffmanJ, NebekerJR: Critical gaps in the world‘s largest electronic medical record: ad hoc nursing narratives and invisible adverse drug events.AAMIA Annu. Symp. Proc.309–312 (2003).
- Pezalla E : Preventing adverse drug reactions in the general population.Manag. Care Interface18 , 49–52 (2005).
- Meyer UA : Pharmacogenetics and adverse drug reactions.Lancet356(9242) , 1667–1671 (2000).
- Phillips KA , VeenstraDL, OrenE, LeeJK, SadeeW: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.JAMA286 , 2270–2279 (2001).
- Beitelshees AL , McLeodHL: Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety.Trends Pharmacol. Sci.27 , 498–502 (2006).
- Lunshof JE , PirmohamedM, GurwitzD: Personalized medicine: decades away?Pharmacogenomics7 , 237–241 (2006).
- Kollek R , van Aken J, Feuerstein G, Schmedders M: Pharmacogenetics, adverse drug reactions and public health. Community Genet.9 , 50–54 (2006).
- Voora D , EbyC, LinderMW et al.: Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost.93 , 700–705 (2005).
- Rieder MJ , ReinerAP, GageBF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352 , 2285–2293 (2005).
- Wadelius M , PirmohamedM: Pharmacogenetics of warfarin: current status and future challenges.Pharmacogenomics J. DOI 10.1038/sj.tpj.6500417 (2006) [Epub ahead of print].
- Grown C , GuptaGR, PandeR: Taking action to improve women‘s health through gender equality and women‘s empowerment.Lancet365 , 541–543 (2005).
Websites
- The Royal Society working group on pharmacogenetics: Personalised medicines: hopes and realities. The Royal Society (2005). www.royalsoc.ac.uk/displaypagedoc.asp?id=15874
- Zika E , GurwitzD, IbarretaD: Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impacts in the EU. The European Commission (2006). http://esto.jrc.es/detailshort.cfm?ID_report=1387
- US FDA: Guidance for Industry: Pharmacogenomic Data Submissions. March (2005). www.fda.gov/cber/gdlns/pharmdtasub.htm
- Summary Minutes of the FDA Clinical Pharmacology Subcommittee Meeting of the Advisory Committee for Pharmaceutical Science. November 14–15 (2005). www.fda.gov/OHRMS/DOCKETS/AC/05/minutes/2005–4194M1.pdf